Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (3)
  • Open Access

    ARTICLE

    Codelivery of anti-CD47 antibody and chlorin e6 using a dual pH-sensitive nanodrug for photodynamic immunotherapy of osteosarcoma

    JIJIE XIAO1, HONG XIAO2, YUJUN CAI3, JIANWEI LIAO1, JUE LIU1, LIN YAO1, SHAOLIN LI1,*

    Oncology Research, Vol.32, No.4, pp. 691-702, 2024, DOI:10.32604/or.2023.030767

    Abstract Osteosarcoma is a malignant tumor originating from bone tissue that progresses rapidly and has a poor patient prognosis. Immunotherapy has shown great potential in the treatment of osteosarcoma. However, the immunosuppressive microenvironment severely limits the efficacy of osteosarcoma treatment. The dual pH-sensitive nanocarrier has emerged as an effective antitumor drug delivery system that can selectively release drugs into the acidic tumor microenvironment. Here, we prepared a dual pH-sensitive nanocarrier, loaded with the photosensitizer Chlorin e6 (Ce6) and CD47 monoclonal antibodies (aCD47), to deliver synergistic photodynamic and immunotherapy of osteosarcoma. On laser irradiation, Ce6 can generate reactive oxygen species (ROS) to… More > Graphic Abstract

    Codelivery of anti-CD47 antibody and chlorin e6 using a dual pH-sensitive nanodrug for photodynamic immunotherapy of osteosarcoma

  • Open Access

    REVIEW

    Opportunities and challenges of CD47-targeted therapy in cancer immunotherapy

    QIUQIANG CHEN1,*, XUEJUN GUO2, WENXUE MA3,*

    Oncology Research, Vol.32, No.1, pp. 49-60, 2024, DOI:10.32604/or.2023.042383

    Abstract Cancer immunotherapy has emerged as a promising strategy for the treatment of cancer, with the tumor microenvironment (TME) playing a pivotal role in modulating the immune response. CD47, a cell surface protein, has been identified as a crucial regulator of the TME and a potential therapeutic target for cancer therapy. However, the precise functions and implications of CD47 in the TME during immunotherapy for cancer patients remain incompletely understood. This comprehensive review aims to provide an overview of CD47’s multifaced role in TME regulation and immune evasion, elucidating its impact on various types of immunotherapy outcomes, including checkpoint inhibitors and… More > Graphic Abstract

    Opportunities and challenges of CD47-targeted therapy in cancer immunotherapy

  • Open Access

    ARTICLE

    CD47 Promotes Human Glioblastoma Invasion Through Activation of the PI3K/Akt Pathway

    Xuejian Liu*1, Xia Wu*1, Yanming Wang, Yuhua Li*, Xiangli Chen*, Wenchuan Yang*, Lihua Jiang*

    Oncology Research, Vol.27, No.4, pp. 415-422, 2019, DOI:10.3727/096504018X15155538502359

    Abstract Cluster of differentiation 47 (CD47) overexpression is common in various malignancies. This study investigated whether CD47 promotes human glioblastoma invasion and, if so, the underlying mechanisms involved. CD47 expression was found to be stronger in tissues of patients with glioblastoma and in various cancer cell lines than in normal controls. CD47 downregulation via siRNA suppressed invasion in vitro, whereas CD47 overexpression through plasmid transfection exerted the opposite effect. However, overexpression or knocking down of CD47 had no effect on cell proliferation. Moreover, CD47 expression was related to Akt phosphorylation at the cellular molecular level. Suppression of Akt with a specific… More >

Displaying 1-10 on page 1 of 3. Per Page